TG4-155

TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM[1][2]. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1[1]. TG4-155 has an EP2 Schild KB of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor[2].

Product Specifications

CAS Number

[1164462-05-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/tg4-155.html

Purity

99.91

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NCCN1C(C)=CC2=C1C=CC=C2)/C=C/C3=CC(OC)=C(OC)C(OC)=C3

Molecular Formula

C23H26N2O4

Molecular Weight

394.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Jiang J, et al. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther. 2013 Feb;344 (2) :360-7.|[2]Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57 (11) :4454-65.|[3]Jiang J, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8) :3149-54.